

Last Updated August 2021

**Peer Reviewed and Refereed Publications:**

1. **Darville T.** Pelvic Inflammatory Disease Due to *Neisseria gonorrhoeae* and *Chlamydia trachomatis*: Immune Evasion Mechanisms and Pathogenic Disease Pathways. *J Infect Dis.* 2021 Aug 16;224(Supplement\_2):S39-S46. doi: 10.1093/infdis/jiab031.PMID: 34396413
2. Zheng X, Zhong W, O'Connell CM, Liu Y, Haggerty CL, Geisler WM, Anyalechi GE, Kirkcaldy RD, Wiesenfeld HC, Hillier SL, Steinkampf MP, Hammond KR, Fine J, Li Y, **Darville T.** Host Genetic Risk Factors for *Chlamydia trachomatis*-Related Infertility in Women. *J Infect Dis.* 2021 Aug 16;224(Supplement\_2):S64-S71. doi: 10.1093/infdis/jiab149.PMID: 34396400
3. McQueen BE, Kollipara A, Gyorke CE, Andrews CW Jr, Ezzell A, Darville T, Nagarajan UM. Reduced uterine tissue damage during **Chlamydia muridarum** infection in TREM-1,3 deficient mice. *Infect Immun.* 2021 Jun 14:IAI0007221. doi: 10.1128/IAI.00072-21. Online ahead of print.PMID: 34125599
4. Wiesenfeld HC, Meyn LA, **Darville T**, Macio IS, Hillier SL. A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease. *Clin Infect Dis.* 2021 Apr 8;72(7):1181-1189. doi: 10.1093/cid/ciaa101.PMID: 32052831 **Free PMC article.** Clinical Trial.
5. de la Maza LM, **Darville TL**, Pal S. **Chlamydia trachomatis** vaccines for genital infections: where are we and how far is there to go? *Expert Rev Vaccines.* 2021 Apr;20(4):421-435. doi: 10.1080/14760584.2021.1899817. Epub 2021 Apr 28. PMID: 33682583
6. Zhong W, **Darville T**, Zheng X, Fine J, Li Y. Generalized multi-SNP mediation intersection-union test. *Biometrics.* 2020 Dec 14. doi: 10.1111/biom.13418. Online ahead of print.PMID: 33316078
7. Gyorke CE, Kollipara A, Allen J 4th, Zhang Y, Ezzell JA, **Darville T**, Montgomery SA, Nagarajan UM. IL-1 $\alpha$  Is Essential for Oviduct Pathology during Genital Chlamydial Infection in Mice. *J Immunol.* 2020 Dec 1;205(11):3037-3049. doi: 10.4049/jimmunol.2000600. Epub 2020 Oct 21. PMID: 33087404
8. Wiringa AE, Ness RB, **Darville T**, Beigi RH, Haggerty CL. *Trichomonas vaginalis*, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease. *Sex Transm Infect.* 2020 Sep;96(6):436-438. doi: 10.1136/sextrans-2019-054079. Epub 2019 Nov 12.PMID: 31719170
9. Tang W, Mao J, Li KT, Walker JS, Chou R, Fu R, Chen W, **Darville T**, Klausner J, Dunbar K, Tucker JD. Pregnancy and fertility-related adverse outcomes associated with *Chlamydia trachomatis* infection: a global systematic review and meta-analysis. *Sex Transm Infect.* 2020 Aug;96(5):322-329. doi: 10.1136/sextrans-2019-053999. PMID: 31836678.
10. Amaral AF, Rahman KS, Kick AR, Cortes LM, Robertson J, Kaltenboeck B, Gerds V, O'Connell CM, Poston TB, Zheng X, Liu C, Omesí SY, **Darville T**, Käser T. Mucosal Vaccination with UV-

Inactivated *Chlamydia suis* Pre-Exposed Outbred Pigs Decreases Pathogen Load and Induces CD4 T-Cell Maturation into IFN- $\gamma$  + Effector Memory Cells. *Vaccines* (Basel). 2020 Jul 2;8(3):E353. doi: 10.3390/vaccines8030353. PMID: 32630694.

11. McQueen B, Kiatthanapaiboon A, Fulcher M, Lam M, Patton K, Powell E, Kollipara A, Madden V, Suchland R, Wyrick P, O'Connell CM, Reidel B, Kesimer M, Randell S, **Darville T**, Nagarajan U. A human fallopian tube epithelial cell culture model to study host responses to *Chlamydia trachomatis* infection. *Infection and Immunity*. 2020 Jun 29;IAI.00105-20. doi: 10.1128/1AI.00105-20. [Epub ahead of print]. PMID 32601108.
12. Dong L, Kollipara A, **Darville T**, Zou F, Zheng X. Semi-CAM: A semi-supervised deconvolution method for bulk transcriptomic data with partial marker gene information. *Sci Rep*. 2020 Mar 25;10(1):5434. doi: 10.1038/s41598-020-62330-2. PMID: 32214192; PMCID: PMC7096458.
13. Wiesenfeld HC, Meyn LA, **Darville T**, Macio IS, Hillier SL. A Randomized Controlled Trial of Ceftriaxone and Doxycycline, with or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease. *Clin Infect Dis*. 2020 Feb 13;ciaa101. doi: 10.1093/cid/ciaa101. Epub ahead of print. PMID: 32052831.
14. Zhong W, Dong L, Poston TB, **Darville T**, Spracklen CN, Wu D, Mohlke KL, Li Y, Li Q, Zheng X. Inferring regulatory networks from mixed observational data using directed acyclic graphs. *Front Genet*. 2020 Feb 07;11:8. Doi: 10.3389/fgene.2020.00008. eCollection 2020 PMID 32127796.
15. Wiringa AE, Ness RB, **Darville T**, Beigi RH, Haggerty CL. *Trichomonas vaginalis*, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease. *Sex Transm Infect*. 2019 Nov 12;sextrans-2019-054079. doi: 10.1136/sextrans-2019-054079. [Epub ahead of print]. PMID: 31719170.
16. Poston TB, Lee DE, **Darville T**, Zhong W, Dong L, O'Connell CM, Wiesenfeld HC, Hillier SL, Sempowski G, Zheng X. Cervical cytokines associated with *Chlamydia trachomatis* susceptibility and protection. *J Infect Dis*. 2019 Jun 19;220(2):330-339. doi: 10.1093/infdis/jiz087. PMID: 30820577.
17. **Darville T**, Albritton H, Zhong W, Dong L, O'Connell CM, Poston TB, Quayle AJ, Goonetilleke N, Wiesenfeld HC, Hillier SL, Zheng X. Anti-chlamydia IgG and IgA are insufficient to prevent endometrial *Chlamydia* infection in women and increased anti-chlamydia IgG is associated with enhanced risk for incident infection. *Am J Reprod Immunol*. 2019 May;81(5):e13103. doi: 10.1111/aji.13103. PMID: 30784128.
18. Petrina MAB, Cosentino LA, Wiesenfeld HC, **Darville T**, Hillier SL. Susceptibility of endometrial isolates recovered from women from clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents. *Anaerobe*. 2019 Apr;56:61-65. doi: 10.1016/j.anaerobe.2019.02.005. PMID: 30753898.
19. O'Connell CM, Brochu H, Girardi J, Harrell E, Jones A, **Darville T**, Seña AC, Peng X. Simultaneous profiling of sexually transmitted bacterial pathogens, microbiome, and

concordant host response in cervical samples using whole transcriptome sequencing analysis. *Microb Cell*. 2019 Jan 24;6(3):177-183. doi: 10.15698/mic2019.03.672. PMID: 30854394.

20. Rahman KS, **Darville T**, Wiesenfeld HC, Hillier SL, Kaltenboeck B. Mixed *Chlamydia trachomatis* peptide antigens provide a specific and sensitive single-well colorimetric enzyme-linked immunosorbent assay for detection of human anti-*C. trachomatis* antibodies. *mSphere*. 2018 Nov 7;3(6). pii: e00484-18. doi: 10.1128/mSphere.00484-18. PMID: 30404936.
21. Zheng X, O'Connell CM, Zhong W, Poston TB, Wiesenfeld HC, Hillier SL, Trent M, Gaydos C, Tseng G, Taylor BD, **Darville T**. Gene Expression Signatures Can Aid Diagnosis of Sexually Transmitted Infection-Induced Endometritis in Women. *Front. Cell. Infect. Microbiol*. 20 September 2018. doi: 10.3389/fcimb.2018.00307. PMID: 30294592.
22. Rahman KS, **Darville T**, Russell AN, O'Connell CM, Wiesenfeld HC, Hillier SL, Lee DE, Kaltenboeck B. Comprehensive Molecular Serology of Human *Chlamydia trachomatis* Infections by Peptide Enzyme-Linked Immunosorbent Assays. *mSphere*. 2018 Aug 1;3(4). pii: e00253-18. doi: 10.1128/mSphere.00253-18. PMID: 30068559.
23. Rahman KS, **Darville T**, Russell AN, O'Connell CM, Wiesenfeld HC, Hillier SL, Chowdhury EU, Juan YC, Kaltenboeck B. Discovery of Human-Specific Immunodominant *Chlamydia trachomatis* B Cell Epitopes. *mSphere*. 2018 Aug 1;3(4). pii: e00246-18. Doi: 10.1128/mSphere.00246-18. PMID: 30068558.
24. Poston TB, O'Connell CM, Girardi J, Sullivan JE, Nagarajan UM, Marinov A, Scurlock AM, **Darville T**. T-independent IFN $\gamma$  and B cells Cooperate to Prevent Mortality Associated with Disseminated *Chlamydia muridarum* Genital Tract Infection. *Infect Immun*. 2018 Apr 16. pii: IAI.00143-18. doi: 10.1128/IAI.00143-18. PMID: 29661927.
25. Zheng X, O'Connell CM, Zhong W, Nagarajan UM, Tripathy M, Lee D, Russell AN, Wiesenfeld H, Hillier S, **Darville T**. Discovery of Blood Transcriptional Endotypes in Women with Pelvic Inflammatory Disease. *J Immunol*. 2018 Apr 15;200(8):2941-2956. Doi: 10.4049/jimmunol.1701658. Epub 2018 Mar 12. PMID: 29531169.
26. Taylor BD, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, **Darville T**. Risk factors for *Mycoplasma genitalium* endometritis and incident infection: a secondary data analysis of the T cell Response Against Chlamydia (TRAC) Study. *Sex Transm Infect*. 2018 Mar 21. pii: sextrans-2017-053376. doi: 10.1136/sextrans-2017-053376. [Epub ahead of print] PMID: 29563165.
27. Zhong G, Brunham RC, de la Maza LM, **Darville T**, Deal C. National institute of allergy and infectious diseases workshop report: "Chlamydia vaccines: the way forward". *Vaccine*. 2017 Oct 30. pii: S0264-410X(17)31483-4. Doi 10.1016/j.vaccine.2017.10.075. [Epub ahead of print] PMID: 29097007.
28. Poston TB, Qu Y, Russell A, Girardi J, Nagarajan U, **Darville T**. A Chlamydia-specific TCR transgenic mouse demonstrates Th1 polyfunctionality with enhanced effector function. *J*

*Immunol.* 2017 Oct 15;199(8):2845-2854. doi: 10.4049/jimmunol.1700914. Epub 2017 Aug 30; PMID: 28855311.

29. Poston TB, Gottlieb SL, **Darville T**. Status of vaccine research and development of vaccines for *Chlamydia trachomatis* infection. *Vaccine*. 2017 Jan 19; PMID: 28111145.
30. Taylor BD, Zheng X, **Darville T**, Zhong W, Konganti K, Abiodun-Ojo O, Ness RB, O'Connell CM, Haggerty CL. Whole-Exome sequencing to identify novel biological pathways associated with infertility after pelvic inflammatory disease. *Sex Transm Dis*. 2017 Jan;44(1):35-41; PMID: 27898568.
31. Russell AN, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, Taylor BD, Picard MD, Flechtner JB, Zhong W, Frazer LC, **Darville T**. Identification of *Chlamydia trachomatis* antigens recognized by T cells from highly exposed women who limit or resist genital tract infection. *J Infect Dis*. 2016 Dec 15; 214(12):1884-1892. PMID: 27738051.
32. Poston TB, **Darville T**. *Chlamydia trachomatis*: Protective Adaptive Responses and Prospects for a Vaccine. *Curr Top Microbiol Immunol*. 2016 Apr 1; PMID: 27033698.
33. Nguyen-Ha PT, Howrie D, Crowley K, Vetterly CG, McGhee W, Berry D, Ferguson E, Polischuk E, Brooks MM, Goff J, Stillwell T, **Darville T**, Thompson AE, Levin JE, Michaels MG, Green M. A Quality Assessment of a Collaborative Model of a Pediatric Antimicrobial Stewardship Program. *Pediatrics*. 2016 May;137(5). pii: e20150316. doi: 10.1542/peds.2015-0316. Epub 2016 Apr 6. PMID:27244775.
34. Russell AN, Zheng X, O'Connell CM, Taylor BD, Wiesenfeld H, Hillier S, Zhong W, **Darville T**. Analysis of factors driving incident and ascending infection and the role of serum antibody in *Chlamydia trachomatis* genital tract infection. *J Infect Dis*. 2016 Feb 15; PMID: 26347571.
35. Qu Y, Frazer LC, O'Connell CM, Tarantal AF, Andrews CW Jr, O'Connor SL, Russell AN, Sullivan JE, Poston TB, Vallejo AN, **Darville T**. Comparable genital tract infection, pathology, and immunity in rhesus macaques inoculated with wild-type or plasmid deficient *Chlamydia trachomatis* serovar D. *Infect Immun*. 2015; PMID: 26216426.
36. Huppler AR, Conti HR, Hernandez-Santos N, **Darville T**, Biswas PS, Gaffen SL. Role of Neutrophils in IL-17-dependent immunity to mucosal candidiasis. *J Immunol*. 2014; 192(4): 1745-52. doi: 10.4049/jimmunol.1302265. PMID: 24442441.
37. Corr TE, Sullivan J, Frazer LC, Andrews CW Jr, O'Connell CM, **Darville T**. Steroids Alone or as Adjunctive Therapy with Doxycycline Fail to Improve Oviduct Damage in Mice Infected with *Chlamydia Muridarum*. *Clin Vaccine Immunol*. 2014; PMID: 24695778.
38. Barral R, Desai R, Zheng X, Frazer LC, Sucato GS, Haggerty CL, O'Connell CM, Zurenski MA, and **Darville T**. Frequency of *Chlamydia trachomatis*-specific T cell interferon- $\gamma$  and interleukin-17 responses in CD-4 enriched peripheral blood mononuclear cells of sexually active adolescent females. *J Reprod Immunol*. 2014; PMID: 24582738.
39. Frazer LC, Scurlock AM, Zurenski MA, Riley MM, Mintus M, Pociask DA, Sullivan JE, Andrews CW Jr, **Darville T**. IL-23 induces IL-22 and IL-17 production in response to *Chlamydia muridarum* genital tract infection, but the absence of these cytokines does not influence disease pathogenesis. *Am J Reprod Immunol*. 2013; 70(6): 472-84. PMID: 24238108.

40. Darville T. Pelvic Inflammatory Disease: Identifying Research Gaps - Proceedings of a Workshop Sponsored by DHHS/NIH/NIAID. November 3-4, 2011. *Sex Transm Dis.* 2013 Oct;40(10):761-7. PMID: 24275724.
41. Frazer LC, Sullivan JE, Zurenski MA, Mintus M, Tomasak TE, Prantner D, Nagarajan UM, and **Darville T**. CD4+ T cell expression of MyD88 is essential for normal resolution of *Chlamydia muridarum* genital tract infection. *J Immunol.* 2013; 191(8): 4269-79. PMID: 24038087.
42. Taylor BD, **Darville T**, and Haggerty CL. Does bacterial vaginosis cause pelvic inflammatory disease? *Sex Transm Dis.* 2013; 40(2): 117-22. PMID: 23324974.
43. Haggerty CL, Panum I, Uldum SA, Bass DC, Olsen J, **Darville T**, Eastman JM, Simhan HN, Roberts JM, Ness RB. *Pregnancy Hypertens.* 2013 Jan;3(1):28-33. doi: 10.1016/j.preghy.2012.09.002. Epub 2012 Sep 28. PMID:26105737
44. Taylor BD, **Darville T**, Ferrell RE, Ness RB, Haggerty CL. Racial variation in Toll-like receptor variants among women with pelvic inflammatory disease. *J Infect Dis.* 2012; 207(6): 940-6. PMID: 23255565.
45. Riley MM, Zurenski MA, Frazer LC, O'Connell CM, Andrews CW, Mintus M, and **Darville T**. The recall response induced by genital challenge with *Chlamydia muridarum* protects the oviduct from pathology but not from reinfection. *Infect Immun.* 2012; 80(6): 2194–2203. PMID: 22431649.
46. Taylor BD, **Darville T**, Ferrell RE, Kammerer CM, Ness RB, Haggerty CL. Variants in toll-like receptor 1 and 4 genes are associated with *Chlamydia trachomatis* among women with pelvic inflammatory disease. *J Infect Dis.* 2012; 205(4): 603-9. PMID: 22238472.
47. Frazer LC, **Darville T**, Chandra-Kuntal Kumar, Andrews CW, Zurenski MA, Mintus M, AbdelRahman, YM, Belland RJ, Ingalls RR, O'Connell CM. Plasmid-Cured *Chlamydia caviae* activates TLR2-dependent signaling and retains virulence in the guinea pig model of genital tract infection. *PLoS One.* 2012; 7(1): e30747. PMID: 22292031.
48. Taylor BD, **Darville T**, Tan C, Bavoil PM, Ness RB, Haggerty CL. The role of *Chlamydia trachomatis* polymorphic membrane proteins in inflammation and sequelae among women with pelvic inflammatory disease. *Infect Dis Obstet Gynecol.* 2011; 2011:989762. PMID: 22028586.
49. Frazer LC, O'Connell CM, Andrews CW Jr, Zurenski MA, **Darville T**. Enhanced neutrophil longevity and recruitment contribute to the severity of oviduct pathology during *C. muridarum* infection. *Infect Immun.* 2011; 79(10): 4029-41. PMID: 21825059.
50. Vonck RA, **Darville T**, O'Connell CM, Jerse AE. Chlamydial infection increases gonococcal colonization in a novel murine coinfection model. *Infect Immun.* 2011; 79(4): 1566-77. PMID: 21245268.
51. Taylor BD, Ness RB, **Darville T**, Haggerty CL. Microbial correlates of delayed care for pelvic inflammatory disease. *Sex Transm Dis.* 2011; 38(5): 434-8. PMID: 21124257.
52. O'Connell CM, AbdelRahman YM, Green E, Darville HK, Saira K, Smith B, **Darville T**, Scurlock AM, Meyer CR, Belland RJ. TLR2 activation by *Chlamydia trachomatis* is plasmid-dependent and

plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by *C. trachomatis* but not by *C. muridarum*. *Infect Immun*. 2011; 79(3): 1044-56. PMID: 21199910.

53. Scurlock AM, Frazer LC, Andrews CW Jr, O'Connell CM, Foote IP, Bailey SL, Chandra-Kuntal K, Kolls JK, **Darville T**. IL-17 contributes to generation of Th1 immunity and neutrophil recruitment during *Chlamydia muridarum* genital tract infection but is not required for macrophage influx or normal resolution of infection. *Infect Immun*. 2011; 79(3): 1349-62. PMID: 21149587.
54. Nagarajan UM, Sikes J, Prantner D, Andrews CW Jr, Frazer L, Goodwin A, Snowden JN, **Darville T**. MyD88 deficiency leads to decreased NK cell gamma interferon production and T cell recruitment during *Chlamydia muridarum* genital tract infection, but a predominant Th1 response and enhanced monocytic inflammation are associated with infection resolution. *Infect Immun*. 2011; 79(1): 486-98. PMID: 21078858.
55. Russell M, **Darville T**, Chandra-Kuntal K, Smith B, Andrews CW Jr, O'Connell CM. Infectivity acts as in vivo selection for maintenance of the chlamydial cryptic plasmid. *Infect Immun*. 2011; 79(1): 98-107. PMID: 20974819.
56. **Darville T**, Hiltke TJ. Pathogenesis of genital tract disease due to *Chlamydia trachomatis*. *J Infect Dis*. 2010; 201Suppl 2:S114-25 Review. PMID: 20524234.
57. Prantner D, **Darville T**, Nagarajan UM. Stimulator of IFN gene is critical for induction of IFN-beta during *Chlamydia muridarum* infection. *J Immunol*. 2010; 184(5): 2551-60. PMID: 20107183.
58. Prantner D, **Darville T**, Sikes JD, Andrews CW Jr, Brade H, Rank RG, Nagarajan UM. Critical role for interleukin-1beta during *Chlamydia muridarum* genital infection and bacterial replication-independent secretion of IL-1beta in mouse macrophages. *Infect Immun*. 2009; 77(12): 5334-46. PMID: 19805535.
59. Kelly KA, Chan AM, Butch A, **Darville T**. Two different homing pathways involving integrin beta7 and E-selecting significantly influence trafficking of CD4 cells to the genital tract following *Chlamydia muridarum* infection. *Am J Reprod Immunol*. 2009; 61(6): 438-45. PMID: 19392981.
60. Kelly KA, Wiley D, Wiesmeier E, Briskin M, Butch A, **Darville T**. The combination of the gastrointestinal integrin (alpha4beta7) and selectin ligand enhances T cell migration to the reproductive tract during infection with *Chlamydia trachomatis*. *Am J Reprod Immunol*. 2009; 61(6): 446-52. PMID: 19392980.
61. Scholnicoff ET, MacGinnitie AJ, Lin PL, **Darville T**. Chronic granulomatous disease in an adolescent with recurrent impetigo and cholecystectomy. *Pediatr Infect Dis J*. 2009; 28(3): 255-7. PMID: 19165129.
62. Nagarajan UM, Prantner D, Sikes JD, Andrews CW Jr, Goodwin AM, Nagarajan S, **Darville T**. Type I IFN signaling exacerbates *Chlamydia muridarum* genital infection in a murine model. *Infect Immun*. 2008; 76(10): 4642-8. PMID: 18663004.
63. Darville T, Welter-Stahl L, Cruz C, Sater AA, Andrews CW Jr, Ojcius DM. Effect of the purinergic receptor P2X7 on Chlamydia infection in cervical epithelial cells and vaginally infected mice. *J Immunol*. 2007; 179(6): 3707-3714. PMID: 17785807.

64. O'Connell CM, Ingalls RR, Andrews CW Jr, Scurlock AM, **Darville T**. Plasmid-deficient *Chlamydia muridarum* fail to induce immune pathology and protect against oviduct disease. *J Immunol*. 2007; 179(6): 4027-34. PMID: 17785841.
65. Reeves DM, Nagarajan U, O'Connell C, Andrews CW, **Darville T**. Lack of an effect of antibiotic treatment on prolonged detection of chlamydial DNA in murine genital tract infection. *Antimicrob Agents Chemother*. 2007 Jul; 51(7): 2646-8. PMID: 17502410.
66. Welter-Stahl L, Ojcius DM, Viala J, Girardin S, Liu W, Delarbre C, Philpott D, Kelly KA, **Darville T**. Stimulation of the cytosolic receptor for peptidoglycan, Nod1, by infection with *Chlamydia trachomatis* or *Chlamydia muridarum*. *Cell Microbiol*. 2006; (6): 1047-57. PMID: 16681844.
67. Verbeke P, Welter-Stahl L, Ying S, Hansen J, Hacker G, **Darville T**, Ojcius D. Recruitment of BAD by the *Chlamydia trachomatis* vacuole correlates with host-cell survival. *PLoS Pathog*. 2006; 2(5): e45. PMID: 16710454.
68. **Darville T**, Wheeler JG, Tucker N, Hackler C, Young K, Maples H. Coercive Treatment of HIV-Positive Children Is Not Justified: In Reply; *Pediatrics*. 2005; 116:1606-1608e.
69. Nagarajan UM, Ojcius DM, Stahl T, Rank RG and **Darville T**. *Chlamydia trachomatis* induces expression of IP-10 and IFN-beta independent of TLR2 and TLR4, but largely dependent on MyD88. *J Immunol*. 2005; 175(1): 450-60. PMID: 15972679.
70. Ojcius DM, **Darville T**, Bavoil PM. Can Chlamydia be stopped? *Sci Amer*. 2005; 292(5): 72-79, PMID: 15882024.
71. Mansour AM, Frenck RW Jr, **Darville T**, Nakhla IA, Wierzba TF, Sultan Y, Bassiouny MI, McCarthy K, Jacobs RF. Relationship between intracranial granulomas and cerebrospinal fluid levels of gamma interferon and interleukin-10 in patients with tuberculous meningitis. *Clin Diagn Lab Immunol*. 2005; 12(2): 363-5. PMID: 15699436.
72. Jungas T, Verbeke P, **Darville T**, and Ojcius DM. Cell Death, BAX activation, and HMGB1 release during infection with Chlamydia. *Microbes Infect*. 2004; 6(13): 1145-55. PMID: 15488733.
73. Roberts GM, Wheeler JG, Tucker NC, Hackler C, Young K, Maples HD, and **Darville T**. Intervention strategies for human immunodeficiency virus infected children poorly adherent with antiretroviral therapy; non-adherence as medical neglect. *Pediatrics*. 2004; 114:e346-e353.
74. **Darville T**, Yedgar S, Krinsky M, Andrews CW Jr, Jungas T, and Ojcius DM. Protection against *Chlamydia trachomatis* infection in vitro and modulation of inflammatory response in vivo by membrane-associated glycosaminoglycans. *Microbes Infect*. 2004; 6(4): 369-76. PMID: 15050964.
75. **Darville T**, Jacobs RF. Management of acute hematogenous osteomyelitis in children. *Pediatr Infect Dis J*. 2004; 23(3): 255-7. PMID: 15014303.
76. Coward K, Tucker N, **Darville T**. Infective endocarditis in Arkansan children from 1990 through 2002. *Pediatr Infect Dis J*. 2003; 22(12): 1048-52. PMID: 14688563.

77. **Darville T**, O'Neill JM, Andrews CW, Jr., Nagarajan UM, Stahl L, and Ojcius DM. Toll-like receptor-2, but not toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. *J Immunol.* 2003; 171:6187-6197. PMID: 14634135.
78. Rank RJ, Bowlin AK, Reed RL, **Darville T**. Characterization of chlamydial genital infection resulting from sexual transmission from male to female guinea pigs and determination of infectious dose. *Infect Immun.* 2003; 71(11): 6148-6154. PMC219580, PMID: 14573630.
79. Coutinho-Silva R, Stahl L, Raymond M-N, Jungas T, Burnstock G, **Darville T**, and Ojcius DM. Inhibition of chlamydial infectious activity due to P2X7 receptor-dependent phospholipase D activation. *Immunity.* 2003; 19(3): 403-12. PMID: 14499115.
80. Perfettini J-L, Ojcius DM, Andrews CW Jr, Korsmeyer SJ, Rank RG, and **Darville T**. Role of proapoptotic BAX in propagation of *Chlamydia trachomatis* and the host inflammatory response. *J Bio Chem.* 2003; 278(11): 9496-9502. PMID: 12509420.
81. Dessus-babus S, **Darville T**, Cuozzo FP, Ferguson K, Wyrick PB. Differences in the innate immune responses (in vitro) to Hela cells infected with the non-disseminating serovar E and the disseminating serovar L2 of *Chlamydia trachomatis*. *Infect Immun.* 2002; 70(6): 3234-3248. PMID: 12011019.
82. Perfettini J-L, **Darville T**, Dautry-Varsat A, Rank RG, Ojcius DM. Inhibition of apoptosis by gamma interferon in cells and mice infected with *Chlamydia muridarum*. *Infect Immun.* 2002; 70(5): 1-6. PMID: 11953396.
83. **Darville T**, Andrews CW Jr, Sikes JD, Fraley PL, Braswell L, Rank RG. Mouse strain-dependent chemokine regulation of the genital tract T helper cell type 1 immune response. *Infect Immun.* 2001; 69(12): 7419-24. PMID: 11705916.
84. James LP, Farrar HC, **Darville T**, Sullivan JE, Givens TG, Kearns GL, Wasserman GS, Simpson PM, Hinson JA. The Pediatric Pharmacology Research Unit Network, National Institute of Child Health and Human Development: Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents. *Clin Pharmacol Ther.* 2001; 70(3): 280-6.
85. **Darville T**, Andrews CW Jr, Sikes, JD, Fraley PL, Rank RG. Early local cytokine profiles in strains of mice with different outcomes from chlamydial genital tract infection. *Infect Immun.* 2001, 69(6): 3556-3561. PMC98334.
86. **Darville T**, Andrews CW Jr, Rank RG. Does inhibition of tumor necrosis factor-alpha affect chlamydial genital tract infection in mice and guinea pigs? *Infect Immun.* 2000, 68(9): 5299-5305. PMC101792.
87. Perfettini J-L, **Darville T**, Gachelin G, Souque P, Huerre M, Dautry-Varsat A, Ojcius DM. Effect of *Chlamydia trachomatis* infection and subsequent tumor necrosis factor alpha secretion on apoptosis in the murine genital tract. *Infect Immun.* 2000; 68(4): 2237-2244. PMC97409.
88. Markham MH, **Darville T**. Morbidity of vaccine-preventable varicella in children in Arkansas. *J Ar Med Soc.* 1999; 96(7): 260-262.
89. **Darville T**, Matheney R. Prevention of perinatal transmission of human immunodeficiency virus in Arkansas. *J Ar Med Soc.* 1998; 95(6): 239-241.



90. Williams DM, Grubbs B, **Darville T**, Kelly K, Rank RG. A role for interleukin-6 in host defense against *Chlamydia trachomatis*. *Infect Immun*. 1998; 66(9): 4564-4567. PMC108560.
91. **Darville T**, Andrews CW Jr, Laffoon KK, Shymasani W, Kishen LR, Rank RG. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. *Infect Immun*. 1997; 65(8): 3065-3073. PMC175432.
92. **Darville T**, Milligan B, Laffoon KK. Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor- $\alpha$  production. *Infect Immun*. 1997; 65(2):366-372. PMC174604.
93. Schutze GE, Hickerson SL, Fortin EM, Schellhase DE, **Darville T**, Gubbins PO, Jacobs RF. Blastomycosis in children. *Clin Infect Dis*. 1996; 22(3): 496-502.
94. Menard J, Tucker NC, **Darville T**. Recent advances in pediatric HIV. *J AR Med Soc*. 1995; 92(4): 165-168.
95. **Darville T**, Laffoon KK, Kishen LR, Rank RG. Tumor necrosis factor- $\alpha$  activity in genital tract secretions of guinea pigs infected with chlamydiae. *Infect Immun*. 1995; 63(12): 4675-4681. PMC173671.
96. Kearns GL, Weber W, Harnisch L, **Darville T**, Blumer JL, Powell K, Wells TG, Jacobs RF. Single-dose pharmacokinetics of cefpirome in pediatric patients. *Clin Drug Invest*. 1995; 10(2): 71-85.
97. **Darville T**, Jacobs RF, Trang JM, Kearns GL. Pharmacokinetic evidence supporting an eight-hour dosing interval for cefotaxime in infants and children. *Clin Drug Invest*. 1995; 9(4): 206-211.
98. **Darville T**, Tabor D, Simpson K, Jacobs RF. Intravenous immunoglobulin modulates human mononuclear phagocyte tumor necrosis factor- $\alpha$  production in vitro. *Pediatric Research*. 1994; 35(4): 397-403.
99. Kearns GL, **Darville T**, Blumer JL, Powell K, Wells TG, Jacobs RF. Single dose pharmacokinetics of cefpodoximeproxetil in infants and children. *Drug Invest*. 1994; 7(5): 221-233.
100. Buchanan GA, **Darville T**. Impact of immunization against *Haemophilus influenzae* type b (HIB) on the incidence of HIB meningitis treated at Arkansas Children's Hospital. *So Med J*. 1994; 87(1): 38-40.
101. Tucker NC, Schutze GE, **Darville T**, Jacobs RF. Diagnosis, care and management of the pediatric HIV/AIDS patients in Arkansas. *J Ar Med Soc*. 1993; 90(6): 258-262.
102. **Darville T**, Giroir B, Jacobs RF. The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy. *Infect*. 1993; 21(51) 279-290.
103. Jacobs RF, **Darville T**, Parks JA, Enderlin G. Cefotaxime treatment of hospitalized children: Safety profile and efficacy. *Clin Infect Dis*. 1992; 14:56-65.

104. **Darville T**, Tabor DR, Theus SA, Jacobs RF. Surface matrix binding alters murine peritoneal mononuclear phagocyte TNF- $\alpha$  and IL-6 induction. *Immun Invest.* 1992; 21(6): 539-552.
105. **Darville T**, Jacobs RF, Lucas RA, Caldwell B. Detection of *Haemophilus influenzae*, type b antigen in cerebrospinal fluid after immunization. *Pediatr Infect Dis J.* 1992; 11(3): 243-244.
106. Kearns G, Jacobs RF, Thomas BR, **Darville T**, Trang JM. Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates. *J Pediatr.* 1989; 114(3): 461-467.